2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

4:30PM-6:00PM: Abstract Number: 2076

Impact of Vasculitis on Employment and Income: An Online Survey of Participants in the Rare Diseases Clinical Research Network – Vasculitis Clinical Research Consortium Patient Contact Registry

Vasculitis II: Population Studies

4:30PM-6:00PM: Abstract Number: 2042

Improving the Overall Pneumococcal Vaccination Rate in Lupus Patients at the Rheumatology Clinic

Quality Measures and Quality of Care I

4:30PM-6:00PM: Abstract Number: 2079

Incidence and Risk of Pneumocystis Jirovecii Pneumonia Following Rituximab Treatment in Granulomatosis with Polyangiitis in the United States: An Analysis from a National Database

Vasculitis II: Population Studies

4:30PM-6:00PM: Abstract Number: 2062

Increased Expression of Response Gene to Complement-32 in Kidney Biopsies from Patients with Lupus Nephritis

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I

4:30PM-6:00PM: Abstract Number: 2073

Jumonji Domain Containing Protein 3 (JMJD3) As a Novel Epigenetic Mechanism of Fibroblast Activation By Regulation of Fra-2

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics I

4:30PM-6:00PM: Abstract Number: 2070

Long Noncoding RNA H19X Is a Master Regulator of Extracellular Matrix Production in Systemic Sclerosis and Other Fibrotic Disease

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics I

4:30PM-6:00PM: Abstract Number: 2085

Minding the Gap: the Use of Nurse Practitioners and Physician Assistants in U.S. Rheumatology Practice to Affect Rheumatology Workforce Shortages

ARHP IV: Clinical Practice, Patient Care and Health Services

4:30PM-6:00PM: Abstract Number: 2055

Myocardial Abnormalities Are Associated with Corrected QT Interval in Patients with Rheumatoid Arthritis without Cardiac Symptoms Assessed Using Cardiac Magnetic Resonance Imaging

Rheumatoid Arthritis – Clinical Aspects III: Prevention of Comorbidity

4:30PM-6:00PM: Abstract Number: 2075

No Detection of Varicella-Zoster Virus in Temporal Arteries of Patients with Giant Cell Arteritis

Vasculitis II: Population Studies

4:30PM-6:00PM: Abstract Number: 2034

Novel Susceptible Genes for Behçet’s Disease Identified By Dense Genotyping of Immune-Related Loci Implicate Host Responses to Microbial Exposure

Genetics, Genomics and Proteomics I

4:30PM-6:00PM: Abstract Number: 2038

Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis

Quality Measures and Quality of Care I

4:30PM-6:00PM: Abstract Number: 2065

Platelet FcγRIIa Polymorphism H131R Associates with Subclinical Atherosclerosis and Increased Platelet Activity in SLE

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I

4:30PM-6:00PM: Abstract Number: 2052

Preoperative Timing of Infliximab and Risk of Post-Operative Infection in a Medicare Cohort

Rheumatoid Arthritis – Clinical Aspects III: Prevention of Comorbidity

4:30PM-6:00PM: Abstract Number: 2053

Prosthetic Joint Infection with Staphylococcus Aureus: Recurrence after Surgical Treatment in U.S. Veterans with and without Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects III: Prevention of Comorbidity

4:30PM-6:00PM: Abstract Number: 2037

Proteostasis Dysregulation and Autoinflammation in Patients with TRNT1 Deficiency

Genetics, Genomics and Proteomics I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].